What are the contraindications to the use of mobosetinib/mobosetinib?

Mobocertinib is an oral targeted drug specifically designed to treat non-small cell lung cancer (NSCLC) with EGFR Exon20 insertion mutations. Although it has clear indications and efficacy advantages, its contraindications need to be strictly controlled to avoid serious adverse effects. First, basic contraindications include patients who are allergic to moboxetinib or its excipients. They may have severe allergic reactions after using the drug, which may even lead to systemic rashes and respiratory failure.

Secondly, mobosetinib is exclusively used to confirm patients with positive EGFR Exon20 insertion mutations. Patients with other EGFR wild-type or common mutations (such as Del19 or L858R) are not indicated. Misuse will not only lack efficacy, but also bear the risk of unnecessary side effects.

However, for patients with severe underlying hepatic insufficiency (Child-Pugh B/C), mobosetinib is not recommended as the first-choice drug; its dose needs to be carefully evaluated, and needs to be initiated and closely monitored under the guidance of a professional physician. Patients with severe renal insufficiency should also use it with caution. Although it is mainly metabolized by the liver, metabolites are excreted through the kidneys, and the cumulative risk cannot be ignored.

In addition, mobosetinib can cause interstitial lung disease (ILD) and prolongation of the QT interval. Therefore, patients with past interstitial lung disease, severe arrhythmias, or taking other QT prolonging drugs (such as certain antiarrhythmic drugs, antipsychotic drugs, etc.) should be contraindicated in use or should undergo close cardiorespiratory monitoring as appropriate.

There is not enough safety data for special groups, such as pregnant women and lactating women, so Mobosetinib is considered contraindicated in these groups. The pros and cons must be weighed and informed consent must be strictly obtained before use. In addition, men and women of childbearing age who want to become pregnant should use contraceptive methods and confirm that there is no risk of childbearing age after stopping the drug for at least several weeks before becoming pregnant.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib